AP
Anand Parikh
Co-Founder & CEO
Faeth designs precision nutrition interventions and combines them with targeted therapies to modulate tumor metabolism in clinical trials across cancers including pancreatic, colorectal, and PI3K-mutated tumors.
Faeth designs precision nutrition interventions and combines them with targeted therapies to modulate tumor metabolism in clinical trials across cancers including pancreatic, colorectal, and PI3K-mutated tumors.
Faeth Therapeutics was founded in 2019 by Pulitzer Prize-winning oncologist Siddhartha Mukherjee (Columbia), Lewis Cantley (Weill Cornell's Meyer Cancer Center, discoverer of PI3K), and Karen Vousden (Francis Crick Institute / Cancer Research UK). The three co-founders concluded that "precision nutrition" was an untapped treatment modality in cancer care, designing metabolically-engineered diets to withhold key nutrients from tumors when combined with existing drugs. Anand Parikh joined as CEO to operationalize the company.
Sensei Biotherapeutics announced the acquisition of Faeth Therapeutics alongside a $200M concurrent private placement to advance Faeth's PIKTOR program in endometrial and breast cancer.
Faeth's Phase 2 DICE trial of oral sapanisertib plus chemotherapy demonstrated a 34% reduction in disease progression risk in ovarian cancer, justifying a Phase 3 design.
Faeth's Phase 1b PIKTOR + paclitaxel combination showed an 80% overall response rate in endometrial cancer and ~11-month median PFS, driving Phase 2 plans.
Faeth and the GOG Foundation launched the first Phase 2 combination trial of sapanisertib-serabelisib (PIKTOR) with paclitaxel in patients with endometrial cancer.
Faeth closed a $47M Series A led by S2G Ventures to advance its precision-nutrition approach in oncology, bringing total funding to $67M.
Series A led by S2G Ventures to advance clinical trials combining precision nutrition with targeted oncology treatments.
Faeth Therapeutics closed a $20M seed round co-led by Khosla Ventures and Future Ventures to turn precision nutrition into a pillar of cancer treatment.
Co-Founder & CEO
Co-Founder
Previously Oncologist & Professor at Columbia University
Pulitzer Prize-winning author of "The Emperor of All Maladies" and oncologist at Columbia University.
Co-Founder
Co-Founder
Previously Director at Weill Cornell Meyer Cancer Center
Discoverer of the PI3K signaling pathway and director of Weill Cornell's Meyer Cancer Center.
Co-Founder
Previously Group Leader; Chief Scientist of Cancer Research UK at Francis Crick Institute
Chief scientist of Cancer Research UK and group leader at the Francis Crick Institute.
$267M raised total
No H1B sponsorship data available for this company.